UCI researchers discover key factor for survival of human embryonic stem cellsFebruary 17, 2006Human embryonic stem cells (hES) offer great hope for the treatment of some devastating diseases, but finding a way to keep enough of these cells usable and healthy for transplantation in patients has been an ongoing problem. Now, scientists at UC Irvine have discovered a way to keep large quantities of these cells alive, a finding that could potentially lead to mass production of hES cells for therapeutic use at lower cost. These findings appear in a paper in the early online version of the journal Nature Biotechnology. UCI stem cell researchers Peter Donovan and Leslie Lock, along with April Pyle of Johns Hopkins University, found that molecules known as neurotrophins have a significant effect on whether hES cells survive in the laboratory. Although stem cells have the ability to self-renew and to differentiate into any cell in the body, it has been a challenge to keep them alive as single cells in an undifferentiated state.
In their studies, Donovan and Lock added neurotrophins to hES cells in the laboratory to see the effect they would have on cell survival. Neurotrophins normally encourage the survival of tissue in the nervous system. When three members of the family of neurotrophin growth factors - brain derived neurotrophic factor (BDNF), neurotrophin 3 (NT-3), and neurotrophin 4 (NT-4) - were added to hES cells in culture, the cells' survival increased 36-fold. "Keeping hES cells alive as single cells has been extremely difficult," Donovan said. "This fact has kept us from producing enough cells to be useful for therapy, and has limited our ability to genetically manipulate the cells, which we must do before they can be transplanted into patients. It appears that if we treat hES cells with neurotrophins, we can produce more of them faster and, hopefully, at much lower cost." Understanding the role that neurotrophins play in stem cell survival could also help researchers with another major problem they face in using hES cells for therapy. Rather than treating disease, undifferentiated stem cells that are transplanted into the body often form tumors instead, causing harm to the patient. A significant challenge has been to prevent the formation of tumors by ensuring that all cells are differentiated before they are transplanted. The studies by Donovan and Lock show that this is even more crucial when that transplantation is made into areas of the body rich in neurotrophins. "Much of the research regarding stem cell therapy today focuses on areas involving the nervous system, such as the spinal cord," Donovan said. "Neurotrophins help the growth of tissues in those areas and are commonly found in the nervous system. Therefore, when we use stem cells for therapy in those areas, we must be especially careful that no undifferentiated cells are transplanted where they could respond to neurotrophins and form tumors." The work by Donovan and Lock provides a potential solution to the problem. By treating stem cells in culture with chemicals that block the action of neurotrophins on hES cells, Donovan said, scientists can kill the undifferentiated stem cells before they are implanted into the body. According to Donovan, the studies also offer further proof that new stem cell lines need to develop beyond those already in existence. Federally approved hES lines currently used for research were not created in the presence of growth factors such as neurotrophins. The work undertaken by Donovan and Lock indicates that cell lines not created in these optimal conditions may eventually mutate and lose their usefulness for therapeutic purposes. This study was funded through grants from the National Institutes of Health and Johns Hopkins University. Donovan and Lock recently joined UCI's Stem Cell Research Center, which provides campus and visiting scientists an infrastructure to capitalize on recent stem cell breakthroughs, particularly in the areas of nerve repair and regeneration. In addition to holding a joint appointment in the School of Biological Sciences and the School of Medicine as a professor of developmental and cell biology and biological chemistry, Donovan is interim co-director of the Stem Cell Research Center. Lock holds appointments as assistant adjunct professor in developmental and cell biology and in biological chemistry. The university also is seeking support to construct a $60 million Stem Cell Research Institute facility aimed at propelling stem cell technology from the research lab to the clinic. About the University of California, Irvine: The University of California, Irvine is a top-ranked university dedicated to research, scholarship and community service. Founded in 1965, UCI is among the fastest-growing University of California campuses, with more than 24,000 undergraduate and graduate students and about 1,400 faculty members. The second-largest employer in dynamic Orange County, UCI contributes an annual economic impact of $3.3 billion. For more UCI news, visit www.today.uci.edu. UC Irvine | |||||||||||||||||||||
|
Related Embryonic Stem Cells Current Events and Embryonic Stem Cells News Articles A link between mitochondria and tumor formation in stem cells Researchers report on a previously unknown relationship between stem cell potency and the metabolic rate of their mitochondria -a cell's energy makers. Stem cells with more active mitochondria also have a greater capacity to differentiate and are more likely to form tumors. Landmark study unlocks stem cell, DNA secrets to speed therapies In a groundbreaking study led by an eminent molecular biologist at Florida State University, researchers have discovered that as embryonic stem cells turn into different cell types, there are dramatic corresponding changes to the order in which DNA is replicated and reorganized. Embryonic stem cells might help reduce transplantation rejection Researchers have shown that immune-defense cells influenced by embryonic stem cell-derived cells can help prevent the rejection of hearts transplanted into mice, all without the use of immunosuppressive drugs. Stem cell regeneration repairs congenital heart defect Mayo Clinic investigators have demonstrated that stem cells can be used to regenerate heart tissue to treat dilated cardiomyopathy, a congenital defect. OU Cancer Institute Scientists Identify New Cancer Stem Cell Marker; Developing Drug to Stop Cancer Recurrence After years of working toward this goal, scientists at the OU Cancer Institute have found a way to isolate cancer stem cells in tumors so they can target the cells and kill them, keeping cancer from returning. Human embryonic stem cell secretions minimized tissue injury after heart attack A novel way to improve survival and recovery rate after a heart attack was reported in the journal Stem Cell Research by scientists at Singapore's Institute of Medical Biology (IMB) and Bioprocessing Technology Institute (BTI) and The Netherlands' University Medical Center Utrecht. Updated guidelines for stem cell research released The National Academies today released amended guidelines for research involving human embryonic stem cells, revising those that were issued in 2005 and updated in 2007. TAU Researchers Create New Stem Cell Screening Tool Stem cell research is the next great leap in medicine. In the future, new tissue grown in a laboratory could replace a failing heart, or new cells take the place of damaged cells in the brain. Stem cell research puts interstate rivalry on hold Victoria and New South Wales have put aside their competitive interstate rivalry to collaborate on a stem cell research project, as announced by Innovation Minister Gavin Jennings and NSW Minister for Science and Medical Research, Verity Firth, today. UC Riverside researcher develops novel method to grow human embryonic stem cells The majority of researchers working with human embryonic stem cells (hESCs) - cells which produce any type of specialized adult cells in the human body - use animal-based materials for culturing the cells. But because these materials are animal-based, they could transmit viruses and other pathogens to the hESCs, making the cells unsuitable for medical use. More Embryonic Stem Cells Current Events and Embryonic Stem Cells News Articles |
|||||||||||||||||||||
|
|||||||||||||||||||||
|
|||||||||||||||||||||